SR classic (n=247) | SR combination (n=351) | ADAPT (n=106) | |||||||

LCG (n=92) | HCG (n=155) | P-value | LCG (n=188) | HCG (n=163) | P-value | LCG (n=43) | HCG (n=63) | P-value | |

eTICI 2 c or greater on first pass for TTO*, n (%) | 29 (32.2) | 81 (56.6) | <0.0001 | 85 (47.2) | 72 (44.7) | 0.65 | 8 (20.0) | 22 (37.3) | 0.09 |

Bailout, n (%)1 | 13 (14.1) | 15 (9.7) | 0.34 | 17 (9.0) | 18 (11.1) | 0.48 | 24 (57.1) | 29 (46.8) | 0.37 |

Number of passes for treatment of target occlusion, n (%) | <0.0001 | 0.63 | 0.83 | ||||||

1–2 | 72 (78.3) | 140 (90.3) | 161 (85.6) | 137 (84.0) | 28 (65.1) | 42 (66.7) | |||

≥3 | 20 (21.7) | 15 (9.7) | 27 (14.4) | 26 (16.0) | 15 (34.9) | 21 (33.3) | |||

eTICI 2 c or greater at end of procedure*, n (%) | 52 (56.5) | 119 (77.8) | 0.00042 | 119 (63.3) | 111 (68.9) | 0.20 | 26 (60.5) | 52 (82.5) | 0.012 |

Symptomatic ICH up to 48 hours post-procedure, n (%) | 2 (2.2) | 3 (1.9) | 0.88 | 3 (1.6) | 4 (2.5) | 0.39 | 0 (0.0) | 3 (4.8) | 0.273 |

NIHSS at 24 hours, mean (SD) | 8.6 (7.7) | 6.0 (6.4) | 0.005 | 7.0 (6.3) | 7.9 (7.6) | 0.34 | 8.1 (7.9) | 6.1 (7.2) | 0.35 |

Embolization to new territory*, n (%) | 0 (0.0) | 2 (1.3) | 0.53(3) | 1 (0.5) | 2 (1.2) | 0.42 | 0 (0.0) | 0 (0.0) | N/A(4) |

Distal emboli*), n (%) | 42 (45.7) | 47 (30.7) | <0.0001 | 88 (47.1) | 71 (44.1) | 0.58 | 23 (53.5) | 23 (36.5) | 0.08(2) |

90-day mRS 0–2, n (%) | 43 (48.9) | 97 (65.1) | 0.04 | 103 (57.2) | 88 (54.3) | 0.51 | 23 (62.2) | 49 (79.0) | 0.07(2) |

*These variables are core lab reported. All other variables are site-reported.

Bailout is defined as switching to another technique for treatment of target occlusion (TTO), or to a procedure other than TTO to improve eTICI. These techniques include treatment of additional clot, distal emboli, embolization to new territory, or stenosis.(2) P-value adjusted for site could not be calculated, so unadjusted P-value presented. Interpret with caution, as unadjusted P-values are smaller (more significant) than adjusted P-values.(3) P-values adjusted for site could not be calculated due to zero cell count. Unadjusted P-value using Fisher’s Exact test are presented. Interpret with caution, as unadjusted P-values are smaller (more significant) than adjusted p-values.

P-value could not be calculated as there were no embolization to new territory in either low or high cervical groups.

BGC, balloon-guided catheter; eTICI, expanded treatment in cerebral infarction; HCG, high cervical group; ICH, intracranial hemorrhage; LCG, low cervical group; mRS, modified Rankin Score.; NHISS, National Institute of Health Stroke Scale.